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Abstract We have previously described an atypical lipoprotein-
binding protein of about 105 kDa (p105) in membranes of
vascular smooth muscle cells (VSMCs) that is distinct from
currently known lipoprotein receptors. In the present work we
have developed a procedure for purification of p105 from human
aortic media. Partial sequencing of purified protein has revealed
identity of p105 with human T-cadherin. Anti-peptide antisera
raised against human T-cadherin recognized a protein spot
corresponding to the purified p105 on two-dimensional Western
blots. The antisera also inhibited LDL binding to p105 on ligand
blots. We conclude that the 105 kDa lipoprotein-binding protein
present in human VSMCs is T-cadherin, an unusual glycosyl-
phosphatidylinositol-anchored member of the cadherin family of
cell-cell adhesion proteins.
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1. Introduction
During the last decade the understanding of both cellular
e¡ects of lipoproteins and mechanisms of cell-lipoprotein in-
teractions has signi¢cantly broadened. It is increasingly rec-
ognized that, quite apart from their lipid-transporting func-
tions, lipoproteins can stimulate a number of cellular
metabolic events by apparently endocytosis-independent
mechanisms. In particular, lipoproteins activate second mes-
senger systems, regulate gene expression and stimulate prolif-
eration in vascular smooth muscle cells (VSMCs) [1^5]. It has
been hypothesized that these processes are mediated by mem-
brane receptor(s) [1,6] that are distinct from known lipopro-
tein receptors [7,8]. We have more recently conducted a search
for candidate signalling receptors in VSMCs using a method
of ligand blotting that exploits the property of lipoprotein
receptors to retain high a⁄nity and selectivity for their ligands
on Western (ligand) blots. Ligand blotting has been widely
and successfully applied for investigation of ligand and inhib-
itor selectivity of apo B,E (LDL) receptor [9], VLDL receptor
[10], LRP [11], gp330/megalin [12], scavenger receptor [13],
lipolysis-stimulated receptor [14] and HDL-binding proteins
[15]. Application of this technique for characterization of lip-
oprotein-binding proteins in VSMC membranes resulted in
detection of a major lipoprotein-binding protein of 105 kDa
(p105) and a minor 130 kDa lipoprotein-binding protein
(p130) [16]. The ligand selectivity and binding properties of
p105 and p130 are apparently identical and clearly distinct
from those of all other recognized lipoprotein receptors [17].
The identity of these atypical lipoprotein-binding proteins was
not known. We have accordingly developed an original pro-
cedure for puri¢cation of p105 from human aortic media and
determined its partial amino acid sequence. This paper de-
scribes the scheme of puri¢cation of p105 and presents data
indicating that p105 is identical with T-cadherin, a protein
belonging to the cadherin family of cell-cell adhesion proteins
[18,19].
2. Materials and methods
2.1. Materials
Electrophoresis reagents were obtained from Bio-Rad Laboratories
(Hercules, USA). Defatted dry milk, Rapilait, was from Migros
(Basel, Switzerland). CHAPS, iminodiacetic acid-agarose, Ampholines
Ph 3.5^10, CNBr-activated Sepharose 4B, protein A-agarose, bu¡ers
and other chemicals were purchased from Sigma Chemical Co. (St.
Louis, USA).
2.2. Ligand and immunoblotting
The method of ligand (LDL) blotting has been fully described pre-
viously [16]. Brie£y, protein samples were solubilized in Laemmli bu¡-
er without reducing agents, electrophoresed on 8% SDS-polyacryla-
mide gels and electroblotted onto nitrocellulose. Nitrocellulose
membranes were pre-blocked in TBSM (5% solution of defatted dry
milk in 150 mM NaCl, 50 mM Tris-HCl, pH 7.4) and incubated at
room temperature in TBSM containing LDLs (100 Wg protein/ml,
unless otherwise stated). After washing with TBSM, the membranes
were incubated with a⁄nity-puri¢ed anti-LDL antibodies conjugated
to peroxidase, washed again and stained by the Ni2-diaminobenzi-
dine method [20]. Quantitative estimates of LDL binding were ob-
tained by scanning of blots (Hewlett Packard Scanjet 4P) and use
of SigmaGel software. Immunoblotting procedures were essentially
the same except that detection of bound primary antibodies was per-
formed using goat anti-rabbit IgG antibodies coupled to peroxidase.
2.3. Puri¢cation of p105 from human aortic media membranes
Microsomal membranes were isolated from human aortic media as
described before [21,16]. The membranes were solubilized in bu¡er A
(20 mM Tris, 5 mM EDTA, 0.2 mM PMSF, pH 8.0) containing 10
mM CHAPS (60 min on ice with stirring) and centrifuged at
100 000Ug for 1.5 h. The supernatant was applied to a column of
DEAE-Toyopearl (5 mg protein/ml gel). The column was washed with
two volumes of bu¡er A, one volume of bu¡er B (20 mM MOPS, 10
FEBS 19710 15-1-98
0014-5793/98/$19.00 ß 1998 Federation of European Biochemical Societies. All rights reserved.
PII S 0 0 1 4 - 5 7 9 3 ( 9 7 ) 0 1 5 6 2 - 7
*Corresponding author. Fax: +7 (95) 414-67-19.
E-mail: bochkov@cardio.med.msu.su
Abbreviations: VSMC, vascular smooth muscle cell ; LDL, low density
lipoprotein; mAb, monoclonal antibody; IEF, isoelectric focusing;
2-D, two-dimensional; GPI, glycosylphosphatidylinositol
FEBS 19710FEBS Letters 421 (1998) 208^212
mM CHAPS, 0.2 mM PMSF, pH 7.2) and then eluted with 3 volumes
of bu¡er B containing 0.5 M NaCl. The eluate was passed over a
column of immobilized iminodiacetic acid (2 mg protein/ml gel) which
had been loaded with Zn2 ions according to the manufacturer’s
protocol, and the column was washed with bu¡er B containing 0.5
M NaCl. The £owthrough and the wash were combined and concen-
trated by ultra¢ltration under the pressure of nitrogen, and then
passed through a column of Sepharose 4B containing immobilized
mAb clone 9B8 (see below). The £owthrough was loaded onto
SDS-containing 8% polyacrylamide gel (4 mg protein per 13.5
cmU0.75 mm slab) and electrophoresed [22]. The gels were stained
with 0.05% Coomassie R-250 water solution, destained in water, and
the band containing p105 (identi¢ed by comparison with a ligand blot
processed in parallel) was excised. The protein was electroeluted from
the gel (Model 422 Electro-Eluter, BioRad), concentrated by ultra-
¢ltration and applied to the ¢rst dimension isoelectrofocusing gels
(tubes 3 mmU8 cm, 5% PAAG, 8 M urea, 2% Triton X-100, 2%
Ampholines pH 3.5^10.0). Isoelectrofocusing was performed at 400
volts overnight, then at 800 volts for 2 h. The tube gels were then ¢xed
with agarose on top of 8% SDS-polyacrylamide slab gels and electro-
phoresed in the Laemmli bu¡er system. The protein spots were de-
tected by Coomassie staining as described above, excised and electroe-
luted. After testing an aliquot for purity by analytical 2-D gel
electrophoresis, the samples were again electrophoresed in 8% SDS-
polyacrylamide gel and transferred onto PVDF membrane by electro-
blotting [23]. The blots were stained with 0.2% Coomassie in 50%
methanol and destained in 50% methanol; the protein spots were
excised, dried under the stream of nitrogen and stored in Eppendorf
tubes until sequencing. The puri¢cation procedure consistently yielded
W10 Wg p105 per 100 mg of starting membrane protein extract.
2.4. Generation of 9B8 monoclonal antibody
This clone was selected after immunization of BALB/c mice with
partially puri¢ed p105. Fusion was performed according to [24] using
mouse myeloma X63-Ag8.653 cell line and PEG 1500. Screening of
mAbs was carried out by a dot-blot procedure using antigen adsorbed
on nitrocellulose membrane. The selected hybridoma was cloned and
then grown in the peritoneal cavity of BALB/c mice. The mAb was
precipitated from ascitic £uid by ammonium sulfate, further puri¢ed
by protein A-chromatography and immobilized on CNBr-activated
Sepharose 4B.
The 9B8 mAb did not recognize p105, but interacted with an un-
known protein having both a molecular weight and pI very close to
those of p105. This immunoa⁄nity step eliminated the 9B8 antigen
which partially overlapped and interfered with further puri¢cation of
p105 from two-dimensional gels.
2.5. Sequencing of p105
Sequencing of p105 was performed in the Laboratory of Protein
Chemistry, Department of Biochemistry (Prof. Paul Jeno), Biocenter,
Basel, Switzerland. Peptide fragments of p105 were generated by tryp-
sin digestion of the protein on PVDF membranes, separated by re-
versed phase HPLC and subjected to gas phase sequencing. Matching
of peptide amino acid sequences in the SWISS-PROT database using
DNA SUN software revealed identity of the fragments with human T-
cadherin (see Fig. 3 for aligned sequences).
2.6. Generation of anti-T-cadherin peptide antibodies
A search for antigenic determinants of human T-cadherin was per-
formed using the Peptide Companion sequence analysis program
package (CohiSoft/PeptiSearch). The algorithm for predicting immu-
nodominant regions is based on the hydrophilicity assessment of an
amino acid sequence and on analysis of the occurrence probability of
various amino acid combinations in the known antigenic determinants
[25,26]. On the basis of these methods potential antigenic determi-
nants were designated and peptides corresponding to the following
amino acid positions of human T-cadherin precursor were synthe-
sized: 140^160; 161^179; 260^271 (Fig. 3). The peptides were pre-
pared by solid phase synthesis on Applied Biosystems 431A Synthe-
sizer using Fmoc-amino acyl polymers (Bachem, Switzerland) and
conjugated with keyhole limpet hemocyanin and bovine serum albu-
min. The content of peptides in conjugates was determined by quan-
titative amino acid analysis. Immunization of rabbits (three animals
for each peptide) with the conjugates was performed according to
standard protocol [20]. All experiments utilizing antibodies were per-
formed using IgG fraction obtained by ammonium sulfate precipita-
tion [20]. The concentration of immunoglobulins was determined by
ELISA.
3. Results
We have developed an original procedure for puri¢cation of
p105 from microsomes obtained from the media layers of
human aortae. The procedure includes solubilization of pro-
teins with CHAPS, three chromatographic (anion-exchange,
metal-chelating and immunoa⁄nity) and two electrophoretic
(one- and two-dimensional) steps (see Section 2). The course
of puri¢cation is illustrated in Fig. 1 which presents character-
istics for Coomassie staining (Panel A) and ligand (LDL)
binding (Panel B) after the di¡erent steps of puri¢cation.
Binding of LDL to the puri¢ed p105 was inhibited by pre-
treatment of the protein with 2-mercaptoethanol and by in-
clusion of EDTA into the incubation medium (Fig. 1C). These
properties are indicative of speci¢c mechanisms of p105-LDL
interaction and are in accordance with our previous observa-
tions in nonfractionated membrane solubilizates of VSMCs
[16].
Purity of the ¢nal preparation was checked by analytical 2-
D gel electrophoresis. Fig. 2 presents Coomassie-stained gels
(panels A, B) and corresponding ligand (LDL) blots (panels
C, D) of starting membrane extract (panels A, C) and of the
¢nal p105 preparation (panels B, D) which was used for de-
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Fig. 1. The course of puri¢cation of p105 and LDL-binding charac-
teristics. Coomassie-stained gels (panel A) and ligand blots (panel
B) are presented to illustrate protein patterns and LDL-binding ac-
tivity of p105 preparations at di¡erent stages of puri¢cation. The
samples are: starting CHAPS extract (a) and preparations after
DEAE (b) and metal-chelating chromatography (c), one- (d) and
two-dimensional (e) gel electrophoresis. Panel C illustrates the abil-
ity of 2-mercaptoethanol and EDTA to inhibit binding of LDL to
p105. 2-Mercaptoethanol was included in the electrophoresis sample
bu¡er, while EDTA (20 mM) was added directly to the LDL incu-
bation medium.
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termination of amino acid sequence. Note that the starting
extract contained a major p105 spot and two minor spots of
the same isoelectric point but slightly di¡erent molecular
weights of W130 and 95 kDa, while the ¢nal preparation
contained only p105. The nature of these additional LDL-
binding proteins (which are also consistently observed in
one-dimensional blots, see Fig. 1) and their relation to p105
is currently under investigation.
Puri¢ed p105 was further processed for determination of
amino acid sequence. Three partial NH2-terminal amino
acid sequences of tryptic fragments from p105 were obtained.
Comparative analysis of these sequences (SWISS-PROT data-
base) revealed identity with the sequence of human T-cadherin
[19] (Fig. 3).
On the basis of known full sequence of human T-cadherin,
three potentially immunogenic peptides were selected for syn-
thesis and used for immunization of rabbits (see Fig. 3 for
positions of peptide residues). All three antibody preparations
(but not control serum) recognized the same 130, 105 and 95
kDa bands on one-dimensional Western blots of aortic mem-
brane extracts, and immunoreactivity colocalized with ligand
(LDL) binding (data not shown). The identity of immuno-
and ligand blotting patterns was also observed on two-dimen-
sional Western blots as illustrated for two antisera in Fig. 2D,
E and F. Nonimmune rabbit antiserum did not interact with
p105 on 2-D blots (data not shown).
Similarly to classical cadherins [27], p105 was resistant to
trypsin in the presence of Ca2, while in EDTA-containing
medium the protein was rapidly degraded with simultaneous
loss of LDL-binding activity (data not shown). Treatment of
cultured human aortic smooth muscle cells with GPI-speci¢c
phospholipase C [18] resulted in a loss of at least 80% of cell-
associated p105 and corresponding accumulation of soluble
protein of the same electrophoretic mobility recognized by
anti-peptide antibody (E. Kuzmenko, manuscript in prepara-
tion). These data demonstrate that p105 is expressed on cell
surface and is anchored in membrane through a GPI group.
Since T-cadherin is the only currently known GPI-anchored
cadherin, these data support our identi¢cation of p105 as T-
cadherin.
We tested antisera against synthetic T-cadherin peptides
140^160, 161^179 and 260^271 for their ability to interfere
with LDL binding to p105. Inclusion of these antibodies dur-
ing incubation of blots with LDLs dose dependently blocked
binding of the lipoprotein (Fig. 4A and B). The most prom-
inent inhibitory e¡ect was exerted by antibodies directed to
the peptide located near the NH2-terminus of mature T-cad-
herin (starting from position 139 of the precursor), while the
antiserum to the peptide positioned closer to C-terminus was
the least e⁄cient (Fig. 4A).
4. Discussion
We have previously demonstrated the existence of atypical
lipoprotein-binding proteins (major p105, minor p130) in
membranes of human and rat VSMCs [16]. Characterization
of lipoprotein-binding properties revealed features of a ligand-
receptor interaction rather than a mere nonspeci¢c adhesion
of lipoprotein to a sticky protein. Speci¢cally, the binding is
selective for LDLs, is divalent cation dependent, requires in-
tact disul¢de bonds in the lipoprotein-binding proteins and
can be inhibited by anti-LDL (apo B) antibodies. Addition-
ally, lipoprotein binding is not enhanced by high ionic
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Fig. 3. Complete amino acid sequence of human T-cadherin (as precursor form) obtained from the SWISS-PROT database. Italics indicate ex-
perimentally derived amino acid sequences of p105 proteolytic fragments. Processed protein contains residues 140 and further. Peptides selected
for synthesis and subsequent use in raising antibodies are underlined. Arrows indicate the start of each peptide.
Fig. 2. Analysis of purity of the ¢nal p105 preparation by two-di-
mensional gel electrophoresis. Starting CHAPS extract and puri¢ed
p105 were analysed either by Coomassie staining of 2-D gels (A, B)
or by 2-D ligand blotting (C, D). Panels E and F represent 2-D
Western blots of the ¢nal p105 preparation stained with 1 to 50 di-
lution of antisera to T-cadherin peptides 140^160 and 260^271, re-
spectively. The left and right sides of the gel are the acidic
(pHW4.5) and the basic (pHW8.5) sides, respectively.
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strength favoring hydrophobic interactions and cannot be in-
hibited by polycations or polyanions [16,17]. The nature/iden-
tities of these lipoprotein-binding proteins was not known. In
this present work we have puri¢ed p105 to homogeneity and
presented evidence that p105 is identical with T-cadherin. This
conclusion is based on the results of direct sequencing of
puri¢ed p105 and the data demonstrating the ability of anti-
peptide antibodies to T-cadherin to react with p105 on West-
ern blots and to block LDL binding to p105 on ligand blots.
Cadherins are plasma membrane proteins mediating selec-
tive cell-cell recognition. They bind to other molecules identi-
cal to themselves situated on adjacent cells ; this phenomenon
is called homophilic binding (reviewed in [28]). Some charac-
teristics of p105 (T-cadherin)/LDL binding correlate with
known properties of these cell adhesion molecules. Firstly,
binding mediated by cadherins requires divalent cations [29]
and LDL binding to p105 (T-cadherin) is inhibited by EDTA
(Fig. 1C; [16]). Secondly, cadherin-mediated cell-cell adhesion
has been shown to be sensitive to dithiothreitol [29] and LDL
binding to p105 (T-cadherin) is decreased after reduction of
samples with 2-mercaptoethanol (Fig. 1C; [16]). Thirdly, the
homotypic interaction site of cadherins is located close to the
NH2-terminus of the molecules and antibodies selectively
blocking E-, P- or N-cadherin activity all recognize epitopes
localized within about 30 residues from the NH2-termini [30] ;
our results with antisera indicate that most prominent inhib-
ition of LDL binding to p105 (T-cadherin) is exerted by the
antibody recognizing a peptide positioned at the NH2-termi-
nus of mature T-cadherin which begins from the position 140
of the precursor (Fig. 4A). These similarities suggest that
mechanisms of LDL/T-cadherin recognition may be analo-
gous to those mediating homophilic cadherin/cadherin inter-
actions.
The present data indicate that cadherins may have a less
stringent ligand selectivity than was previously assumed. Our
unequivocal identi¢cation of T-cadherin as a lipoprotein-bind-
ing protein shows that cadherins have the potential to interact
with soluble ligands. Such heterophilic interactions may be
relevant to alteration of cadherin-cadherin recognition and
thereby the functions of T-cadherin in intercellular binding/
communication. Further studies on the role of lipoproteins in
regulation of cell-cell interactions and T-cadherin-mediated
intracellular signalling are required to examine these issues.
Acknowledgements: We thank Prof. Paul Jeno and Thiery Mini for
assistance with sequencing of p105 and Drs. Alexander Itkes and
Thomas Niermann for help in analysis of amino acid sequences and
for valuable discussions. This work was supported by grants from
INTAS (# 93-3260), the Russian Foundation for Basic Research (#
95-04-12253 and 97-04-49521), the Swiss National Foundation (# 31-
41874.94) and the Swiss Heart Foundation.
References
[1] Block, L.H., Knorr, M., Vogt, E., Locher, R., Vetter, W., Gro-
scurth, P., Qiao, B.-Y., Pometta, D., James, R., Regenass, M.
and Pletscher, A. (1988) Proc. Natl. Acad. Sci. USA 85, 885^
889.
[2] Bochkov, V., Tkachuk, V., Buhler, F. and Resink, T. (1992)
Biochem. Biophys. Res. Commun. 188, 1295^1304.
[3] Hahn, A.W.A., Ferracin, F., Buhler, F.R. and Pletscher, A.
(1991) Biochem. Biophys. Res. Commun. 178, 1465^1471.
[4] Bjorkerud, S. and Bjorkerud, B. (1994) Arterioscler. Thromb. 14,
288^298.
[5] Resink, T.J., Bochkov, V.N., Hahn, A.W.A., Philippova, M.P.,
Buhler, F.R. and Tkachuk, V.A. (1995) J. Vasc. Res. 32, 328^
338.
[6] Tkachuk, V.A., Kuzmenko, Ye.S., Resink, T.J., Stambolsky,
D.V. and Bochkov, V.N. (1994) Mol. Pharmacol. 46, 1129^1137.
[7] Sachinidis, A., Locher, R. and Vetter, W. (1991) Am. J. Hyper-
tens. 4, 274^279.
[8] Bochkov, V.N., Matchin, Yu.G., Fuki, I.V., Lyakishev, A.A. and
Tkachuk, V.A. (1992) Atherosclerosis 96, 119^124.
[9] Daniel, T.O., Schneider, W.J., Goldstein, J.L. and Brown, M.S.
(1983) J. Biol. Chem. 258, 4606^4611.
[10] Battey, F.D., Gafvels, M.E., FitzGerald, D.J., Argraves, W.S.,
Chappell, D.A., Strauss III, J.F. and Strickland, D.K. (1994)
J. Biol. Chem. 269, 23268^23273.
[11] Lund, H., Takahashi, K., Hamilton, R.L. and Havel, R.J. (1989)
Proc. Natl. Acad. Sci. USA 86, 9318^9322.
[12] Willnow, T.E., Goldstein, J.L., Orth, K., Brown, M.S. and Herz,
J. (1992) J. Biol. Chem. 267, 26172^26180.
[13] Kodama, T., Reddy, P., Kishimoto, C. and Krieger, M. (1988)
Proc. Natl. Acad. Sci. USA 85, 9238^9242.
[14] Yen, F.T., Mann, C.J., Guermani, L.M., Hannouche, N.F., Hu-
bert, N., Hornick, C.A., Bordeau, V.N., Agnani, G. and Bihain,
B.E. (1994) Biochemistry 33, 1172^1180.
[15] Koller, E., Koller, F. and Binder, B.R. (1989) J. Biol. Chem. 264,
12412^12418.
FEBS 19710 15-1-98
Fig. 4. Inhibition of LDL/p105 binding by anti-T-cadherin peptide antibodies. Equal amounts (50 Wg) of p105 preparation obtained after metal
(Zn2) chelate chromatography were electrophoresed, blotted onto nitrocellulose and incubated either with 40 Wg/ml of LDL in the presence of
increasing concentrations of total IgG (panel A), or with varying concentrations of LDL in the presence or absence of a ¢xed amount (2500
Wg/ml) of immunoglobulins anti 140^160 (panel B). LDL binding was quantitated using peroxidase-conjugated anti-LDL. Comparable results
with respect to both the degree of inhibition and relative e⁄ciency of di¡erent antisera were obtained in two additional experiments.
V.A. Tkachuk et al./FEBS Letters 421 (1998) 208^212 211
[16] Kuzmenko, Y.S., Bochkov, V.N., Philippova, M.P., Tkachuk,
V.A. and Resink, T.J. (1994) Biochem. J. 303, 281^287.
[17] Bochkov, V.N., Tkachuk, V.A., Philippova, M.P., Stambolsky,
D.V., Buhler, F.R. and Resink, T.J. (1996) Biochem. J. 317, 297^
304.
[18] Ranscht, B. and Dours-Zimmermann, M.T. (1991) Neuron 7,
391^402.
[19] Tanihara, H., Sano, K., Heimark, R.L., St-John, T. and Suzuki,
S. (1994) Cell Adhes. Commun. 2, 15^26.
[20] Harlow, E. and Lane, D. (1988) Antibodies: A Laboratory Man-
ual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor,
NY.
[21] Matlib, M.A. (1984) Methods Pharmacol. 5, 12^24.
[22] Laemmli, U. (1970) Nature 227, 680^685.
[23] Towbin, H., Staehelin, T. and Gordon, J. (1979) Proc. Natl.
Acad. Sci. USA 76, 4350^4354.
[24] Kohler, G. and Milstein, C. (1975) Nature 256, 495^497.
[25] Hopp, T.P. and Woods, K.R. (1993) Proc. Natl. Acad. Sci. USA
90, 2141^2145.
[26] Welling, G.W., Weijer, W.I., Van der Zee, R. and Welling-Wes-
ter, S. (1985) FEBS Lett. 188, 215^218.
[27] Nose, A. and Takeichi, M. (1986) J. Cell Biol. 103, 2649^2658.
[28] Takeichi, M. (1991) Science 251, 1451^1455.
[29] Takeichi, M. (1977) J. Cell Biol. 75, 464^474.
[30] Nose, A., Tsuji, K. and Takeichi, M. (1990) Cell 61, 147^155.
FEBS 19710 15-1-98
V.A. Tkachuk et al./FEBS Letters 421 (1998) 208^212212
